Etanercept: A clinical review of current and emerging indications

Shikha Nanda, Joan M. Bathon

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


The recent development of inhibitors of TNF-α has provided the opportunity for a more targeted and highly effective approach to the treatment of chronic inflammatory illnesses such as rheumatoid arthritis. Since the initial approval of etanercept as a treatment for rheumatoid arthritis, additional indications, including psoriatic arthritis, juvenile rheumatoid arthritis and ankylosing spondylitis, have also received FDA approval. More than 220,000 patients have been treated with etanercept so far. This review summarises the body of knowledge accumulated so far on etanercept (Enbrel®) since it entered the market 5 years ago. 2004

Original languageEnglish (US)
Pages (from-to)1175-1186
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Issue number5
StatePublished - May 2004


  • Etanercept
  • Rheumatoid arthritis
  • Tumour necrosis factor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Etanercept: A clinical review of current and emerging indications'. Together they form a unique fingerprint.

Cite this